Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals identifies, develops, and commercializes novel therapies for rare diseases. Their main product is Livmarli for the treatment of Alagille syndrome. On March 14 the FDA approved Livmarli for infants three months old. The medicine was previously only approved for children at least 1 year of age. As of now, the company reports a negative EPS, but we would expect, given the positive sales trend, EPS will turn positive in the next quarters, hence a further share price appreciation is possible.